Systemic lupus erythematosus (SLE) is an autoimmune disease that involves dysregulation of B and T cells. A tolerogenic peptide, designated hCDR1, ameliorates disease manifestations in SLE-afflicted mice. In the present study, the effect of treatment with hCDR1 on the CD74/macrophage migration inhibitory factor (MIF) pathway was studied. We report here that B lymphocytes from SLE-afflicted mice express relatively elevated levels of CD74, compared with B cells from healthy mice. CD74 is a receptor found in complex with CD44, and it binds the pro-inflammatory cytokine MIF. The latter components were also up-regulated in B cells from the diseased mice, and treatment with hCDR1 resulted in their down-regulation and in reduced B-cell survival. Furthermore, up-regulation of CD74 and CD44 expression was detected in brain hippocampi and kidneys, two target organs in SLE. Treatment with hCDR1 diminished the expression of those molecules to the levels determined for young healthy mice. These results suggest that the CD74/MIF pathway plays an important role in lupus pathology.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by impaired B-cell and T-cell functions and it is associated with serological and clinical manifestations that involve multiple organ systems. 1 Because B and T cells play a pivotal role in SLE pathogenesis, successful treatment strategies for the disease should optimally target both cell types. For a specific treatment of SLE, a peptide designated hCDR1, 2 which is based on the sequence of the complementarity-determining region (CDR) -1 of an autoantibody, 3 was designed and shown to ameliorate lupus manifestations in both spontaneous and induced models of SLE. 4, 5 The mechanisms underlying the beneficial effects of hCDR1 are manifested through the induction of CD4 + CD25 +6 and CD8 + CD28 )7 regulatory T cells, immunomodulation of cytokines, 4 apoptosis 8 and induction of regulatory molecules. [9] [10] [11] Serologically, SLE is characterized by the presence of high titres of autoantibodies and abnormal B-cell activation and differentiation. 12 The regulation of mature B-cell survival involves multiple mechanisms. The B-cell receptor provides survival signals essential for maintaining the mature B-cell pool. In addition, the B-cell activating factor (BAFF) is required for successful survival and maturation of splenic B cells. 13 We demonstrated that BAFF, which was found to be elevated in sera from patients with SLE and lupus-prone mice, 14, 15 was down-regulated following treatment with hCDR1 in SLE-afflicted mice. 16 Recently, we described an additional mechanism that regulates B-cell survival, which depends on CD74 (the cell surface form of invariant chain, li). [17] [18] [19] CD74 is a type II integral membrane protein containing a transmembrane region and a luminal domain that functions as a MHC class II chaperone. 20 Part of the CD74 molecule, modified by the addition of chondroitin sulphate, is expressed on 
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antigen-presenting cells, monocytes and B cells, and interacts with CD44. 21, 22 Macrophage migration inhibitory factor (MIF) binds to the CD74 extracellular domain on macrophages, consequently initiating a signalling pathway. 23 Our studies have shown that CD74 expressed on B cells is directly involved in shaping the B-cell repertoire by regulating mature B-cell survival. [24] [25] [26] It was reported that in MRL/lpr SLE-prone mice, deficiency of MIF resulted in attenuated glomerulonephritis and prolonged survival. 27 Furthermore, elevated serum levels of MIF correlated with increased incidence of organ damage in patients with lupus. 28 Therefore, in the present study, we analysed the expression of the CD74/MIF pathway in (New Zealand Black · New Zealand White) F 1 (BWF 1 ) SLE-afflicted mice and investigated how treatment with the tolerogenic peptide, hCDR1, affected the CD74/MIF pathway. We demonstrate here the elevated expression of molecules of the CD74/MIF pathway on B cells and in two target organs, namely, brain hippocampi and kidneys of SLE-afflicted mice. Treatment with hCDR1 down-regulated the expression of these molecules in association with up-regulation of B-cell apoptosis.
Materials and methods

Mice
Female BWF 1 mice were obtained from the Jackson Laboratory (Bar Harbor, ME). Mice were handled under protocols approved by the Weizmann Institute Animal Care and Use Committee according to international guidelines.
Peptides and treatment
The hCDR1, 2 with sequence GYYWSWIRQPPGKGEE-WIG, based on the CDR1 of a human monoclonal autoantibody, 3 was synthesized by Polypeptide Laboratories (Torrance, CA). A peptide containing the same amino acids as hCDR1, with a scrambled order (SKGIP-QYGGWPWEGWRYEI), designated scrambled peptide, was used as a control and PBS was used as a vehicle. Eight-month-old BWF 1 mice with established disease were divided into three groups (containing 8 to 12 mice) and injected subcutaneously with hCDR1, the scrambled control peptide (both 50 lg per mouse) or vehicle alone, once a week for 10 weeks. Mice were followed for their clinical status [anti-double-stranded (ds) DNA autoantibodies and proteinuria] and at the end of treatment were killed and kidneys were analysed for the presence of immune complex deposits. 4 Measurement of dsDNA-specific autoantibodies Anti-dsDNA antibodies were detected using k phage dsDNA, as previously described. 4 
Proteinuria
Proteinuria was measured by a standard semi-quantitative test, using an Albustix kit (Bayer Diagnostic, Newbury, UK).
Immunohistology
Detection of glomerular immune complex deposits was performed as described earlier. 4 The intensity of immune complex deposits was graded as follows: 0, no immune complex deposits; 1, low intensity; 2, moderate intensity; and 3, high intensity of immune complexes. The immune complex deposit analysis was performed by two people blinded to whether the mice belonged to control or experimental groups.
Separation of B cells
CD45R/B220
+ cells were isolated from spleens of experimental mice using BD IMagnet (BD Biosciences, Chicago, IL), according to the manufacturer's instructions. Briefly, splenocytes were suspended with CD45R/B220 particles, and incubated at 4°for 30 min. The cells labelled with IMag particles were placed in the BD IMagnet and were separated from unlabelled cells by magnetic force. The process was repeated once. The isolated cells were analysed by FACS following each experiment and were found to be 96-99% pure.
MIF stimulation
For MIF stimulation, 1 · 10 7 spleen cells were incubated for 24 hr in RPMI-1640 medium containing 100 ng/ml recombinant MIF as described previously. 29 
Flow cytometry
Splenocytes (1 · 10 6 cells) were incubated with anti-CD74 (Santa Cruz Biotechnologies, Santa Cruz, CA), anti-CD44 (Southern Biotechnology Associates, Birmingham, AL), or anti-B220 (eBioscience, San Diego, CA) specific antibodies and analysed by flow cytometry. For Annexin-V and propidium iodide staining, cells were analysed using the Phosphatidyl Serine Detection Kit (IQ Products, Groningen, the Netherlands), according to the manufacturer's instructions, and were analysed by FACS.
Cell lysates and Western blot analysis
Lysates extracted from either B cells, brain hippocampi or kidneys were separated on SDS-PAGE as described previously. 8 The membranes were incubated with the antibodies anti-CD74, anti-Bcl-2, anti-Bcl-xL (Santa Cruz Biotechnologies) and anti-b-actin (Sigma-Aldrich, Poole, UK) antibodies. Membranes were incubated with the appropriate second antibody coupled to horseradish peroxidase. Detection was performed using the enhanced chemiluminescence method. Densitometric units were determined using the NIH IMAGE program (National Institutes of Health, Bethesda, MD).
Real-time reverse transcription-PCR
Total RNA was prepared from isolated B cells, brain hippocampi or kidneys using TRI Reagent (Molecular Research Center, Cincinnati, OH). Complementary DNA was prepared and real-time reverse transcription-PCR was performed using the LightCycler system (Roche, Mannheim, Germany), according to the manufacturer's instructions. The following primer sequences were used (forward and reverse, respectively):
. The levels of b-actin were used for normalizing the expression levels of the studied genes. Results are presented relative to the vehicle-treated group (considered as 100%).
Statistical analyses
Statistical analysis was performed using Mann-Whitney U-test and Student's t-test. Values of P < 0Á05 were considered significant.
Results
Amelioration of disease manifestations in BWF 1 mice with established SLE by treatment with hCDR1
Eight-month-old BWF 1 mice with established disease were divided into three groups (n = 8 to n = 12) and injected subcutaneously with hCDR1, the scrambled peptide (both 50 lg per mouse) or vehicle alone, once a week for 10 weeks. The clinical data of three treatment experiments are summarized in Table 1 . It can be seen in the table that mice treated with the vehicle or with the control peptide exhibited high levels of anti-dsDNA autoantibodies. In mice treated with hCDR1, however, these levels were significantly reduced. Treatment with hCDR1 also ameliorated kidney disease, as indicated by a decrease of both proteinuria and the intensity of immune complex deposits in the kidneys as compared with mice treated with the vehicle or with the control peptide. Proteinuria, anti-dsDNA autoantibodies and immune complex deposits could not be detected in young (2 months old) mice.
CD74 is up-regulated in B cells from SLE-afflicted mice
CD74 acts as a mediator of B-cell proliferation and survival by initiating a signalling cascade following MIF binding. 17, 19 We therefore determined the CD74 mRNA levels in B cells from 8-month-old SLE-afflicted mice with established disease (defined as 100%) in comparison with its levels in B cells from 2-month-old young, healthy control mice. As shown in Fig. 1(a) , CD74 mRNA levels were significantly elevated in the B cells of SLE-afflicted mice compared with its levels in the cells of young mice. The levels of CD74 in B cells of mice with SLE were further determined at the protein level by Western blotting. The results of a representative blot of CD74 from three experiments performed are presented in Fig. 1(b) . CD74 protein levels were elevated in B cells derived from SLE-afflicted mice compared with those of young healthy controls.
Treatment with hCDR1 down-regulates the expression of molecules of the CD74/MIF pathway CD44 was found to be essential for the MIF-induced signalling cascade. 22, 23 It was of interest to determine whether the expression of CD44 required for the CD74-induced cascade 19 is also up-regulated in the SLE-diseased Table 1 . Effects of treatment with hCDR1 on systemic lupus erythematosus manifestations
Systemic lupus eryhtematosus-afflicted BWF 1 mice were treated once a week with subcutaneous injections of the vehicle, hCDR1, or a control peptide for 10 weeks. 2 Results are of sera from mice that were bled after the end of treatment. Dilution of sera 1 : 250. 3 Statistical evaluation was based on the Mann-Whitney U-test to compare the vehicle-treated group with the remaining treatment groups. 4 Proteinuria was always measured at about the same time of the day and all mice in an experimental cohort were tested together. mice and whether their ligand, MIF, is similarly affected. Furthermore, the ability of hCDR1 to immunomodulate the latter molecules was studied. To this end, RNA was extracted from purified spleen-derived B cells of mice from vehicle, hCDR1 or control peptide-treated mice, obtained at the end of the experiments, and was examined by real-time reverse transcription-PCR. Figure 2 presents the percentage gene expression of MIF and its receptor complex components (CD74 and CD44) in the three treatment groups. The figure shows that treatment with hCDR1 significantly down-regulated the expression levels of the studied molecules, whereas treatment with the control peptide either did not affect their expression or slightly up-regulated the expression (in the case of MIF). Western blot analysis, shown in Fig. 3(a) , confirmed that, in agreement with the mRNA expression levels, treatment with hCDR1 resulted in reduced expression of CD74 protein in B lymphocytes, compared with the expression of the latter in vehicle and control peptide-treated mice. We also examined the cell surface expression of the receptor complex components CD74 and CD44 on B cells from spleens of BWF 1 mice that were treated with hCDR1 or vehicle only, using flow cytometry. As shown in Fig. 3(b) , B cells derived from hCDR1-treated mice expressed lower cell surface levels of CD74 (13Á8%) and CD44 (30Á4%) compared with B cells from the vehicle-treated mice (23Á8% and 39%, respectively). Figure 3(c) shows the significant down-regulation in the mean percentage change, determined in three individual experiments, of surface expression of CD74 and CD44 in B cells from SLE-afflicted mice following hCDR1 treatment compared with vehicle-treated mice.
Treatment with hCDR1 down-regulates anti-apoptotic molecules in B cells and up-regulates the expression of a pro-apoptotic molecule resulting in elevated apoptosis
Systemic lupus erythematosus is associated with the loss of B-cell tolerance, B-cell dysregulation and autoantibody production. 30 To determine the CD74/MIF downstream signalling cascade in B cells from SLE-afflicted mice, we tested the production of the anti-apoptotic molecules Bcl-2 and Bcl-xL, and of the pro-apoptotic molecule Caspase-8 and assessed the effect of treatment with hCDR1 on their expression. Figure 4 (a) presents the mean levels of the anti-apoptotic Bcl-2 and Bcl-xL gene expression relative to the expression in the vehicle-treated group. As shown, the expression of Bcl-2 and Bcl-xL was significantly reduced in B cells of hCDR1-treated mice, compared with B cells of vehicle-treated (P = 0Á03 and P = 0Á01) or control peptide-treated (P = 0Á0001 and P = 0Á05) mice, respectively. The down-regulating effect of hCDR1 on the latter genes was also confirmed at the protein level by Western blot analysis. Figure 4(b) shows that the expression of the pro-apoptotic Caspase-8 was significantly up-regulated in B cells of hCDR1-treated mice (P = 0Á001 and 0Á02, respectively), compared with B cells of vehicle-treated or control-peptide-treated mice. The up-regulating effect of hCDR1 on Caspase-8 was also confirmed at the protein level using Western blot analysis. Hence, hCDR1 down-regulates the anti-apoptotic molecules Bcl-2 and Bcl-xL, which were elevated, and up-regulates the pro-apoptotic molecule Caspase-8, which was diminished, in B cells of SLE-afflicted mice.
We further investigated the association between the expression levels of the anti-apoptotic and pro-apoptotic molecules and the rates of apoptosis in B cells from the experimental mice. Figure 5(a) shows the B220 + cells that were stained for Annexin-V out of the propidium iodide-negative cells. An increase in the percentage of Annexin-V-positive cells was found in B cells of hCDR1-treated mice compared with the vehicle-treated and control-peptide-treated mice. To directly demonstrate whether the up-regulation of B-cell apoptosis by hCDR1 was mediated through the down-regulation of MIF (Fig. 2) , we incubated spleen cells isolated from vehicle-treated or hCDR1-treated mice in the presence or absence of MIF and analysed them by Annexin-V staining. It can be seen that the addition of MIF to the vehicle-treated B cells induced almost no change in the low levels of apoptosis, as determined by the Annexin-V staining. The figure shows that the number of Annexin-V-positive cells was increased in the hCDR1-treated cells but the addition of MIF to the latter cells resulted in a significant reduction of B-cell apoptosis. Hence, MIF, CD74 and CD44 regulate B-cell survival in SLE-afflicted mice and following hCDR1 treatment the expression of these molecules and their downstream cascade are diminished.
Down-regulation of CD74 and CD44 expression in brain hippocampi and kidneys of lupus-prone mice treated with hCDR1
Kidney and central nervous system (CNS) involvement are common in SLE. We demonstrated previously that treatment with hCDR1 ameliorated kidney damage, 4, 6, 7, [31] [32] [33] CNS pathology and cognitive behaviour 5 in the SLEafflicted mice. It was therefore of importance to determine the status of molecules in the CD74/MIF pathway in the brains and kidneys of mice with SLE and the effect of treatment with hCDR1 on the latter. Figure 6(a) shows the mean levels of CD74 and CD44 gene expression in brain hippocampi of hCDR1-treated, control peptidetreated and young healthy mice relative to the expression in the vehicle-treated group (defined as 100%). As can be seen, the mean expression of the CD74 and CD44 genes was significantly reduced in brain hippocampi of hCDR1-treated mice compared with vehicle-treated and controlpeptide-treated mice. Figure 7(a) shows similar results for the expression of CD74 and CD44 in mRNA of kidneys of the different treatment groups. Thus, treatment with hCDR1 diminished the expression of these molecules to levels comparable with those determined in the young, free-of-disease mice. The down-regulating effects of hCDR1 on gene expression was specific because the control peptide did not decrease the expression of CD74 and CD44 and even increased it in some cases in correlation with the clinical status of the control peptide-treated mice. The diminished expression of CD74 in the hippocampi and kidneys following treatment with hCDR1 was also confirmed at the protein level, as demonstrated by Western blot analysis (Figs 6b, 7b ).
Discussion
The main findings of the present study are that the CD74/MIF pathway plays a role in the pathogenesis of lupus and treatment with the tolerogenic peptide, hCDR1, that ameliorates SLE manifestations, and affects the molecules involved in this pathway. Hence, B cells of BWF 1 SLE-afflicted mice over-expressed CD74, CD44 and their ligand, the pro-inflammatory cytokine, MIF. Induction of the CD74/MIF pathway in B cells of SLE-diseased mice was associated with their increased survival, which was diminished following hCDR1 treatment. Furthermore, CD74 and CD44 were up-regulated in kidneys and brains, which are common target organs in SLE. Treatment with hCDR1 down-regulated the expression of CD44. To the best of our knowledge this is the first report of up-regulated expression of MIF and its receptor components in B cells and in disease-affected organs of SLE-afflicted mice and of the immunomodulation of this pathway by a tolerogenic peptide. It was reported that MIF induced proliferation 34 and inhibited apoptosis. 35 In B cells, MIF was reported to initiate a signalling cascade that involves nuclear factor-jB (NF-jB) activation in a CD74-and CD44-dependent manner. 19 We showed that activation of CD74 by MIF on B-chronic lymphocytic leukaemia cells, initiates a signalling cascade that involves NF-jB activation, resulting in interleukin-8 secretion, which promotes cell survival. 36 Similar to the effects of MIF in SLE, mice overproducing BAFF were shown to develop an SLE-like disease and to exhibit B-cell activation of the classical and alternative NF-jB-signalling pathways. 37 In agreement, we reported that hCDR1 reduced the elevated BAFF production in SLE-afflicted mice and that signalling through the NF-jB pathways was involved in the inhibition of BAFF by treatment with hCDR1. 16 The up-regulation of the CD74/MIF pathway in B cells from SLE-diseased mice was associated with elevated expression of the anti-apoptotic molecules Bcl-2 and BclxL, with diminished expression of the pro-apoptotic Caspase-8 and with a better cell survival. The rate of B-cell apoptosis from hCDR1-treated mice was elevated. However, addition of MIF to B cells from hCDR1-treated mice resulted in decreased apoptosis rates comparable to those observed in B cells of vehicle-treated mice suggesting that MIF was involved in the mechanism by which hCDR1 up-regulated B-cell apoptosis. Consistent with the finding that treatment with hCDR1 increased the apoptosis rate of B cells by down-regulating the CD74/MIF pathway, we reported previously that hCDR1 reduced the expression of genes of the anti-apoptotic molecules Bcl-xL and Pim-2 in B cells, in association with their diminished differentiation and maturation, through the down-regulation of the BAFF pathway. 16 Kidneys and CNS are major target organs in SLE. The fact that both CD74 and CD44 were up-regulated in kidneys and brain hippocampi of mice with established lupus suggests that those molecules are involved in the pathogenesis of the disease. Lupus nephritis is characterized by pathogenic autoantibodies that cross-react with glomerular antigens, immune complex formation and complement activation leading subsequently to glomerular damage and elevated proteinuria. 38, 39 Lupus in the CNS is mediated via leucocyte infiltration 40 and brain-reactive autoantibodies. 41, 42 Those autoantibodies form immune complex deposits and are capable of causing neural cell injury and cytokine-induced brain inflammation. 43 The beneficial effects of hCDR1 were manifested by reduced kidney damage and improved CNS pathology, resulting in better survival rates of the treated mice. 4, 5 The fact that amelioration of lupus nephritis and CNS lupus following treatment with hCDR1 was associated with the downregulation of the expression of CD74 and CD44 in these target organs may suggest that the beneficial effects of hCDR1 are via a mechanism that involves the CD74/MIF pathway. It was demonstrated that MIF played a pathogenic role in experimental glomerulonephritis 44 and MIF )/) lupus-prone MRL/lpr mice exhibited significantly reduced renal manifestations. 27 Both MIF and CD74 were up-regulated in rat bladder during inflammation. 45 In addition, expression of CD44 and MHC class II antigens were up-regulated in diseased kidneys. 46 Moreover, expression of CD74 was found to be up-regulated in microglia 47 and in neurofibrillary tangles 48 in the brains of patients with Alzheimer's disease. It is noteworthy that in addition to the role played by CD44 in the CD74/MIF pathway in B cells, expression of CD44 was shown to be increased in patients with SLE 49, 50 in correlation with disease activity. 50 In agreement, we demonstrated an up-regulation in CD44 expression on T cells of mice with SLE-associated responses. Treatment with hCDR1 down-regulated the expression of the latter molecule. 51 Our present results, as well as previous data, indicate that treatment with hCDR1 affects a number of cell types and pathways. Figure 8 summarizes schematically our updated knowledge on the effects of treatment of SLEaffected mice with hCDR1 on T and B cells. As illustrated in the Fig. 8 , the expression of CD74/CD44 complex in B cells of the treated mice is down-regulated along with down-regulation of the ligand of this complex, MIF, which results in suppressed expression of survival molecules, (e.g. Bcl-xL). Previous studies suggested that suppression of NF-jB signalling mediated the latter, 17, 19 in agreement with our findings following down-regulation of BAFF in the hCDR1-treated mice. 16 In addition to the inhibitory effect of hCDR1 on the state of activation of B cells, 8 the resultant enhancement of B-cell apoptosis may lead to the reduced production of dsDNA specific autoantibodies. In the T-cell compartment, however, hCDR1 induced CD4 and CD8 regulatory T cells, 6, 7 up-regulated the expression of Bcl-xL, and led to decreased rates of T-cell apoptosis and inhibition of T-cell activation. 8, 9 As a result, the production of pathogenic cytokines was significantly down-regulated. The reduced production of autoantibodies and pathogenic cytokines is associated with clinical amelioration of SLE manifestations.
In conclusion, the present work has shown the involvement of the CD74/MIF pathway in the development of pathogenic B cells and in SLE-afflicted target organs. Moreover, treatment with the tolerogenic peptide, hCDR1, ameliorates disease manifestations, at least in part, by affecting this pathway.
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